The critical immune checkpoint targets for ICIs in glioma include programmed cell death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). The gene discussed is CTLA4; the disease is central nervous system cancer.